

YOUR VISION IS OUR VISION™

Oxurion To Participate in Upcoming Investor Conferences

October 18, 2022

Leuven, BELGIUM, Boston, MA, US – October 18, 2022 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that it will participate in two upcoming investor conferences.

Investival Showcase - London, UK

Date: Monday, November 14, 2022

Tom Graney, CEO will be delivering a presentation and both he and Michael Dillen, CBO, will be available for one-on-one meetings.

US

BTIG Ophthalmology Day - Virtual

Date: Tuesday, November 29, 2022

Tom Graney, CEO, will be delivering a presentation and will be available for one-on-one meetings.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For further information please contact:

Oxurion NV

Tom Graney Conway Communications

Chief Executive Officer Beth Kurth

Tel: +32 16 75 13 10 bkurth@conwaycommsir.com tom.graney@oxurion.com

Michael Dillen

Chief Business Officer

Tel: +32 16 75 13 10

Christopher Brinzey

michael.dillen@oxurion.com Tel: +1 617 835 9304

Chris.Brinzey@westwicke.com